Compare BioNano Genomics Inc (BNGO) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Realty Income Corp — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while Realty Income Corp trades at $62.3 (market cap $58.56B). The key difference: Realty Income Corp is far larger — about 4287× BioNano Genomics Inc's market cap, and Realty Income Corp pays a 5.25% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | O | |
|---|---|---|
Market Cap | $13.66M | $58.56B |
Sector | Health | Real Estate |
52-Week High | $4.92 | $67.56 |
52-Week Low | $1.06 | $55.93 |
Enterprise Value | $16.26M | $89.19B |
Dividend Yield | — | 5.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Realty Income (O) trades at $62.43, up 0.87% with a bearish technical signal despite bullish oscillators. The REIT reported three consecutive quarterly EPS misses but maintains strong fundamentals with 92.56% gross margins and 21.23% net income margin. Recent news highlights a $875 million convertible notes offering and the company's 115th consecutive dividend increase, supporting its monthly dividend reputation. Revenue growth continues from $5.3B in 2024 to $5.7B in 2025, though debt-to-asset ratio has risen to 39.93%.
The stock presents a mixed outlook with analyst consensus at Buy (41%) and $67.29 price target offering 7.8% upside. Key opportunities include reliable dividends and portfolio expansion into data centers, while risks involve rising leverage and interest rate sensitivity. Technical resistance at $62-63 levels may cap near-term gains despite oversold RSI conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
